Bellon Christine 4

What Happened
Christine Bellon, Chief Legal Officer of Beam Therapeutics (BEAM), sold 1,371 shares in an open-market transaction on January 22, 2026 at $34.00 per share, for total proceeds of $46,614. This was a sale (not a purchase); sales, especially those executed under a pre-set plan, are often routine and do not necessarily signal a change in personal view.

Key Details

• Transaction date: January 22, 2026; reported on Form 4 filed January 26, 2026 (appears timely under the two-business-day rule).
• Price and amount: 1,371 shares sold at $34.00 per share, total $46,614.
• Transaction type: S = Sale (open market/private sale per filing).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Bellon on September 16, 2025.

Context
Rule 10b5-1 plans allow insiders to set up scheduled trades in advance; trades under such plans are generally considered routine and are intended to avoid questions about timing. This filing reports a straightforward sale of shares rather than option exercises, gifts, or awards.